Gemini Therapeutics, INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSan Francisco, CA
SAM.gov UEIHLNQFLHUXEG2
Gemini Therapeutics is focused on advancing aldoxorubicin, a tumor-targeted anthracycline drug. The company supplies capital and operational expertise to bring aldoxorubicin to patients, with analyses showing it delivers higher tumor exposure than doxorubicin while better preserving cardiac function in soft tissue sarcoma studies.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Gemini Therapeutics, INC | San Francisco | CA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.